Day One Biopharma Files Definitive Proxy Statement
Ticker: DAWN · Form: DEF 14A · Filed: Apr 11, 2025 · CIK: 1845337
Sentiment: neutral
Topics: proxy-statement, governance, shareholder-meeting
TL;DR
Day One Biopharma DEF 14A filed. Vote on directors & auditors for June 2nd meeting.
AI Summary
Day One Biopharmaceuticals, Inc. filed a definitive proxy statement (DEF 14A) on April 11, 2025, for its annual meeting of stockholders on June 2, 2025. The filing outlines the company's governance, executive compensation, and proposals to be voted on by shareholders, including the election of directors and ratification of its independent registered public accounting firm.
Why It Matters
This filing provides shareholders with crucial information regarding company leadership, executive pay, and voting matters, enabling informed participation in corporate governance.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEF 14A) that provides information to shareholders and does not inherently indicate new risks.
Key Players & Entities
- Day One Biopharmaceuticals, Inc. (company) — Registrant
- 0001140361-25-013462 (filing_id) — Accession Number
- 20250411 (date) — Filing Date
- 20250602 (date) — Meeting Date
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or definitive proxy statement, is used by companies to solicit proxies from shareholders for an upcoming meeting, providing details on matters to be voted upon, such as director elections and executive compensation.
When is the shareholder meeting for Day One Biopharmaceuticals, Inc.?
The shareholder meeting is scheduled for June 2, 2025.
Who is the filer of this proxy statement?
Day One Biopharmaceuticals, Inc. is the registrant and filer of this proxy statement.
What is the company's primary business according to the SIC code?
The company's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
What is the company's principal executive office address?
The company's business address is 2000 Sierra Point Parkway, Suite 501, Brisbane, CA 94005.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 11, 2025 regarding Day One Biopharmaceuticals, Inc. (DAWN).